[Federal Register Volume 68, Number 42 (Tuesday, March 4, 2003)]
[Notices]
[Page 10254]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-4975]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Advisory Committee for Pharmaceutical Science; Amendment of 
Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    The Food and Drug Administration (FDA) is announcing an amendment 
to the notice of meeting of the Advisory Committee for Pharmaceutical 
Science. This meeting was announced in the Federal Register of February 
3, 2003 (68 FR 5297). The amendment is being made to reflect a change 
in the Agenda portion of the document. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Kathleen Reedy or LaNise Giles, Center 
for Drug Evaluation and Research (HFD-21), Food and Drug 
Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers 
Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 12539. Please call the Information Line for 
up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of February 3, 2003 
(68 FR 5297), FDA announced that a meeting of the Advisory Committee 
for Pharmaceutical Science would be held on March 12 and 13, 2003. On 
page 5298, in the first column, the second sentence in the Agenda 
portion of the document is amended to read as follows:
    On March 13, 2003, the committee will: (1) Discuss and provide 
direction for future subcommittee: Pharmacology/Toxicology 
Subcommittee; (2) receive an update on the Office of Pharmaceutical 
Science research projects; (3) discuss and provide comments on dose 
content uniformity, parametric interval test for aerosol products; (4) 
discuss and provide comments on bioequivalence/bioavailability of 
endogenous drugs; and (5) discuss and provide comments on comparability 
protocols.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: February 26, 2003.
William K. Hubbard,
Associate Commissioner for Policy and Planning.
[FR Doc. 03-4975 Filed 3-3-03; 8:45 am]
BILLING CODE 4160-01-S